{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T16:44:11Z","timestamp":1775925851852,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National natural science"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Duchenne muscular dystrophy (DMD) is a devastating X-linked neuromuscular disorder caused by various defects in the dystrophin gene and still no universal therapy. This study aims to identify the hub genes unrelated to excessive immune response but responsible for DMD progression and explore therapeutic siRNAs, thereby providing a novel treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Top ten hub genes for DMD were identified from GSE38417 dataset by using GEO2R and PPI networks based on Cytoscape analysis. The hub genes unrelated to excessive immune response were identified by GeneCards, and their expression was further verified in <jats:italic>mdx<\/jats:italic> and C57 mice at 2 and 4 months (M) by (RT-q) PCR and western blotting. Therapeutic siRNAs were deemed as those that could normalize the expression of the validated hub genes in transfected C2C12 cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>855 up-regulated and 324 down-regulated DEGs were screened from GSE38417 dataset. Five of the top 10 hub genes were considered as the candidate genes unrelated to excessive immune response, and three of these candidates were consistently and significantly up-regulated in <jats:italic>mdx<\/jats:italic> mice at 2\u00a0M and 4\u00a0M when compared with age-matched C57 mice, including <jats:italic>Col1a2, Fbn1<\/jats:italic> and <jats:italic>Fn1<\/jats:italic>. Furthermore, the three validated up-regulated candidate genes can be significantly down-regulated by three rational designed siRNA (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p><jats:italic>COL1A2<\/jats:italic>, <jats:italic>FBN1<\/jats:italic> and <jats:italic>FN1<\/jats:italic> may be novel biomarkers for DMD, and the siRNAs designed in our study were help to develop adjunctive therapy for Duchenne muscular dystrophy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12891-024-07206-6","type":"journal-article","created":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T05:02:15Z","timestamp":1716008535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Identification of hub genes and therapeutic siRNAs to develop novel adjunctive therapy for Duchenne muscular dystrophy"],"prefix":"10.1186","volume":"25","author":[{"given":"Na","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhikai","family":"Xiahou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zilian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongchun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,18]]},"reference":[{"key":"7206_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/BF00275183","volume":"66","author":"H Moser","year":"1984","unstructured":"Moser H. Duchenne muscular dystrophy: pathogenetic aspects and genetic prevention. Hum Genet. 1984;66:17\u201340.","journal-title":"Hum Genet"},{"key":"7206_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamaneurol.2013.4908","volume":"71","author":"K Anthony","year":"2014","unstructured":"Anthony K, Arechavala-Gomeza V, Ricotti V, Torelli S, Feng L, Janghra N, Tasca G, Guglieri M, Barresi R, Armaroli A, et al. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping. JAMA Neurol. 2014;71:32\u201340. https:\/\/doi.org\/10.1001\/jamaneurol.2013.4908.","journal-title":"JAMA Neurol"},{"key":"7206_CR3","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/S0960-8966(02)00140-2","volume":"12","author":"M Eagle","year":"2002","unstructured":"Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002;12:926\u20139.","journal-title":"Neuromuscul Disord"},{"key":"7206_CR4","doi-asserted-by":"publisher","unstructured":"Sun C, Shen L, Zhang Z, Xie X. Therapeutic strategies for Duchenne muscular dystrophy: an update. Genes (Basel). 2020;11. https:\/\/doi.org\/10.3390\/genes11080837.","DOI":"10.3390\/genes11080837"},{"key":"7206_CR5","doi-asserted-by":"publisher","unstructured":"Shimizu-Motohashi Y, Komaki H, Motohashi N, Takeda Si, Yokota T, Aoki Y. Restoring Dystrophin expression in Duchenne muscular dystrophy: current status of therapeutic approaches. J Pers Med. 2019;9. https:\/\/doi.org\/10.3390\/jpm9010001.","DOI":"10.3390\/jpm9010001"},{"key":"7206_CR6","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","volume":"81","author":"M Shirley","year":"2021","unstructured":"Shirley M, Casimersen. First approval. Drugs. 2021;81:875\u20139. https:\/\/doi.org\/10.1007\/s40265-021-01512-2.","journal-title":"Drugs"},{"key":"7206_CR7","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S, Viltolarsen. First approval. Drugs. 2020;80:1027\u201331. https:\/\/doi.org\/10.1007\/s40265-020-01339-3.","journal-title":"Drugs"},{"key":"7206_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/humu.22758","volume":"36","author":"CL Bladen","year":"2015","unstructured":"Bladen CL, Salgado D, Monges S, Foncuberta ME, Kekou K, Kosma K, Dawkins H, Lamont L, Roy AJ, Chamova T, et al. The TREAT-NMD DMD Global Database: analysis of more than 7,000 duchenne muscular dystrophy mutations. Hum Mutat. 2015;36:395\u2013402. https:\/\/doi.org\/10.1002\/humu.22758.","journal-title":"Hum Mutat"},{"key":"7206_CR9","doi-asserted-by":"publisher","unstructured":"Lu Q-L, Yokota T, Takeda Si, Garcia L, Muntoni F, Partridge T. The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy. Mol Ther. 2011;19. https:\/\/doi.org\/10.1038\/mt.2010.219.","DOI":"10.1038\/mt.2010.219"},{"key":"7206_CR10","first-page":"1202","volume":"11","author":"Q Nguyen","year":"2019","unstructured":"Nguyen Q, Yokota T. Antisense oligonucleotides for the treatment of cardiomyopathy in Duchenne muscular dystrophy. Am J Transl Res. 2019;11:1202\u201318.","journal-title":"Am J Transl Res"},{"key":"7206_CR11","doi-asserted-by":"publisher","unstructured":"Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2016;CD003725. https:\/\/doi.org\/10.1002\/14651858.CD003725.pub4.","DOI":"10.1002\/14651858.CD003725.pub4"},{"key":"7206_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1212\/WNL.8.5.359","volume":"8","author":"E Ronzoni","year":"1958","unstructured":"Ronzoni E, Wald S, Berg L, Ramsey R. Distribution of high energy phosphate in normal and dystrophic muscle. Neurology. 1958;8:359\u201368.","journal-title":"Neurology"},{"key":"7206_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/0026-0495(87)90113-2","volume":"36","author":"MM Chi","year":"1987","unstructured":"Chi MM, Hintz CS, McKee D, Felder S, Grant N, Kaiser KK, Lowry OH. Effect of Duchenne muscular dystrophy on enzymes of energy metabolism in individual muscle fibers. Metabolism. 1987;36:761\u20137.","journal-title":"Metabolism"},{"key":"7206_CR14","doi-asserted-by":"publisher","unstructured":"Zab\u0142ocka B, G\u00f3recki DC, Zab\u0142ocki K. Disrupted Calcium Homeostasis in Duchenne muscular dystrophy: a common mechanism behind Diverse consequences. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms222011040.","DOI":"10.3390\/ijms222011040"},{"key":"7206_CR15","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1093\/hmg\/ddy258","volume":"27","author":"YS Gallot","year":"2018","unstructured":"Gallot YS, Straughn AR, Bohnert KR, Xiong G, Hindi SM, Kumar A. MyD88 is required for satellite cell-mediated myofiber regeneration in dystrophin-deficient mdx mice. Hum Mol Genet. 2018;27:3449\u201363. https:\/\/doi.org\/10.1093\/hmg\/ddy258.","journal-title":"Hum Mol Genet"},{"key":"7206_CR16","doi-asserted-by":"publisher","unstructured":"Grounds MD, Terrill JR, Al-Mshhdani BA, Duong MN, Radley-Crabb HG, Arthur PG. Biomarkers for Duchenne muscular dystrophy: myonecrosis, inflammation and oxidative stress. Dis Model Mech. 2020;13. https:\/\/doi.org\/10.1242\/dmm.043638.","DOI":"10.1242\/dmm.043638"},{"key":"7206_CR17","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.redox.2016.08.016","volume":"9","author":"JR Terrill","year":"2016","unstructured":"Terrill JR, Duong MN, Turner R, Le Guiner C, Boyatzis A, Kettle AJ, Grounds MD, Arthur PG. Levels of inflammation and oxidative stress, and a role for taurine in dystropathology of the Golden Retriever muscular dystrophy dog model for Duchenne muscular dystrophy. Redox Biol. 2016;9:276\u201386. https:\/\/doi.org\/10.1016\/j.redox.2016.08.016.","journal-title":"Redox Biol"},{"key":"7206_CR18","doi-asserted-by":"crossref","unstructured":"Andrew Fire* SX, Mary K, Montgomery*,; Steven A, Kostas*\u2020 SE. D.C.C.M. Potent and specific genetic interference by double stranded RNA in Caenorhabditis elegans. Nature. 1998;39:806\u201311.","DOI":"10.1038\/35888"},{"key":"7206_CR19","doi-asserted-by":"crossref","unstructured":"Sayda M, Elbashir* JH. Winfried Lendeckel*,; Abdullah Yalcin*, K.W.T.T. duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494\u20138.","DOI":"10.1038\/35078107"},{"key":"7206_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nm828","volume":"9","author":"E Song","year":"2003","unstructured":"Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, Chen J, Shankar P, Lieberman J. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med. 2003;9:347\u201351. https:\/\/doi.org\/10.1038\/nm828.","journal-title":"Nat Med"},{"key":"7206_CR21","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11427-018-9438-y","volume":"63","author":"PE Saw","year":"2020","unstructured":"Saw PE, Song EW. siRNA therapeutics: a clinical reality. Sci China Life Sci. 2020;63:485\u2013500. https:\/\/doi.org\/10.1007\/s11427-018-9438-y.","journal-title":"Sci China Life Sci"},{"key":"7206_CR22","doi-asserted-by":"publisher","unstructured":"Soule B, Tirucherai G, Kavita U, Kundu S, Christian R. Safety, tolerability, and pharmacokinetics of BMS-986263\/ND-L02-s0201, a novel targeted lipid nanoparticle delivering HSP47 siRNA, in healthy participants: a randomised, placebo-controlled, double-blind, phase 1 study. J Hepatol. 2018;68. https:\/\/doi.org\/10.1016\/s0168-8278(18)30442-2.","DOI":"10.1016\/s0168-8278(18)30442-2"},{"key":"7206_CR23","doi-asserted-by":"publisher","unstructured":"Meyer P, Notarnicola C, Meli AC, Matecki S, Hugon G, Salvador J, Khalil M, Feasson L, Cances C, Cottalorda J, et al. Skeletal ryanodine receptors are involved in impaired myogenic differentiation in Duchenne muscular dystrophy patients. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms222312985.","DOI":"10.3390\/ijms222312985"},{"key":"7206_CR24","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1111\/jpc.12868","volume":"51","author":"EM Yiu","year":"2015","unstructured":"Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. J Paediatr Child Health. 2015;51:759\u201364. https:\/\/doi.org\/10.1111\/jpc.12868.","journal-title":"J Paediatr Child Health"},{"key":"7206_CR25","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1093\/bioinformatics\/btm254","volume":"23","author":"S Davis","year":"2007","unstructured":"Davis S, Meltzer PS. GEOquery: a bridge between the Gene expression Omnibus (GEO) and BioConductor. Bioinformatics. 2007;23:1846\u20137.","journal-title":"Bioinformatics"},{"key":"7206_CR26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27\u201330.","journal-title":"Nucleic Acids Res"},{"key":"7206_CR27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25:25\u20139.","journal-title":"Nat Genet"},{"key":"7206_CR28","doi-asserted-by":"publisher","first-page":"W199","DOI":"10.1093\/nar\/gkz401","volume":"47","author":"Y Liao","year":"2019","unstructured":"Liao Y, Wang J, Jaehnig EJ, Shi Z, Zhang B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 2019;47:W199\u2013W205. https:\/\/doi.org\/10.1093\/nar\/gkz401.","journal-title":"Nucleic Acids Res"},{"key":"7206_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.4155\/fmc.09.12","volume":"1","author":"G Zinzalla","year":"2009","unstructured":"Zinzalla G, Thurston DE. Targeting protein-protein interactions for therapeutic intervention: a challenge for the future. Future Med Chem. 2009;1:65\u201393. https:\/\/doi.org\/10.4155\/fmc.09.12.","journal-title":"Future Med Chem"},{"key":"7206_CR30","doi-asserted-by":"publisher","first-page":"D362","DOI":"10.1093\/nar\/gkw937","volume":"45","author":"D Szklarczyk","year":"2017","unstructured":"Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 2017;45:D362\u20138. https:\/\/doi.org\/10.1093\/nar\/gkw937.","journal-title":"Nucleic Acids Res"},{"key":"7206_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/35075138","volume":"411","author":"H Jeong","year":"2001","unstructured":"Jeong H, Mason SP, Barab\u00e1si AL, Oltvai ZN. Lethality and centrality in protein networks. Nature. 2001;411:41\u20132.","journal-title":"Nature"},{"key":"7206_CR32","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1101\/gr.1239303","volume":"13","author":"P Shannon","year":"2003","unstructured":"Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498\u2013504.","journal-title":"Genome Res"},{"key":"7206_CR33","doi-asserted-by":"publisher","first-page":"70271","DOI":"10.18632\/oncotarget.20082","volume":"8","author":"C Sun","year":"2017","unstructured":"Sun C, Yuan Q, Wu D, Meng X, Wang B. Identification of core genes and outcome in gastric cancer using bioinformatics analysis. Oncotarget. 2017;8:70271\u201380. https:\/\/doi.org\/10.18632\/oncotarget.20082.","journal-title":"Oncotarget"},{"issue":"Suppl 4","key":"7206_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1752-0509-8-S4-S11","volume":"8","author":"C-H Chin","year":"2014","unstructured":"Chin C-H, Chen S-H, Wu H-H, Ho C-W, Ko M-T, Lin C-Y. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):11. https:\/\/doi.org\/10.1186\/1752-0509-8-S4-S11.","journal-title":"BMC Syst Biol"},{"key":"7206_CR35","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, Kaul A, Kinnett K, McDonald C, Pandya S, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77\u201393. https:\/\/doi.org\/10.1016\/S1474-4422(09)70271-6.","journal-title":"Lancet Neurol"},{"key":"7206_CR36","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1093\/hmg\/ddu735","volume":"24","author":"C Giordano","year":"2015","unstructured":"Giordano C, Mojumdar K, Liang F, Lemaire C, Li T, Richardson J, Divangahi M, Qureshi S, Petrof BJ. Toll-like receptor 4 ablation in mdx mice reveals innate immunity as a therapeutic target in Duchenne muscular dystrophy. Hum Mol Genet. 2015;24:2147\u201362. https:\/\/doi.org\/10.1093\/hmg\/ddu735.","journal-title":"Hum Mol Genet"},{"key":"7206_CR37","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.15252\/emmm.201403967","volume":"6","author":"K Mojumdar","year":"2014","unstructured":"Mojumdar K, Liang F, Giordano C, Lemaire C, Danialou G, Okazaki T, Bourdon J, Rafei M, Galipeau J, Divangahi M, et al. Inflammatory monocytes promote progression of Duchenne muscular dystrophy and can be therapeutically targeted via CCR2. EMBO Mol Med. 2014;6:1476\u201392. https:\/\/doi.org\/10.15252\/emmm.201403967.","journal-title":"EMBO Mol Med"},{"key":"7206_CR38","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1093\/hmg\/ddn129","volume":"17","author":"M Wehling-Henricks","year":"2008","unstructured":"Wehling-Henricks M, Sokolow S, Lee JJ, Myung KH, Villalta SA, Tidball JG. Major basic protein-1 promotes fibrosis of dystrophic muscle and attenuates the cellular immune response in muscular dystrophy. Hum Mol Genet. 2008;17:2280\u201392. https:\/\/doi.org\/10.1093\/hmg\/ddn129.","journal-title":"Hum Mol Genet"},{"key":"7206_CR39","doi-asserted-by":"publisher","unstructured":"M\u00e1zala DA, Novak JS, Hogarth MW, Nearing M, Adusumalli P, Tully CB, Habib NF, Gordish-Dressman H, Chen Y-W, Jaiswal JK, et al. TGF-\u03b2-driven muscle degeneration and failed regeneration underlie disease onset in a DMD mouse model. JCI Insight. 2020;5. https:\/\/doi.org\/10.1172\/jci.insight.135703.","DOI":"10.1172\/jci.insight.135703"},{"key":"7206_CR40","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/jcsm.12414","volume":"10","author":"P Zhang","year":"2019","unstructured":"Zhang P, He J, Wang F, Gong J, Wang L, Wu Q, Li W, Liu H, Wang J, Zhang K, et al. Hemojuvelin is a novel suppressor for Duchenne muscular dystrophy and age-related muscle wasting. J Cachexia Sarcopenia Muscle. 2019;10:557\u201373. https:\/\/doi.org\/10.1002\/jcsm.12414.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"7206_CR41","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.bbadis.2019.01.002","volume":"1865","author":"J R\u00f3g","year":"2019","unstructured":"R\u00f3g J, Oksiejuk A, Gosselin MRF, Brutkowski W, Dymkowska D, Nowak N, Robson S, G\u00f3recki DC, Zab\u0142ocki K. Dystrophic mdx mouse myoblasts exhibit elevated ATP\/UTP-evoked metabotropic purinergic responses and alterations in calcium signalling. Biochim Biophys Acta Mol Basis Dis. 2019;1865:1138\u201351. https:\/\/doi.org\/10.1016\/j.bbadis.2019.01.002.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"7206_CR42","doi-asserted-by":"publisher","first-page":"5428","DOI":"10.1080\/21655979.2021.1967029","volume":"12","author":"X Lai","year":"2021","unstructured":"Lai X, Chen J. C-X-C motif chemokine ligand 12: a potential therapeutic target in Duchenne muscular dystrophy. Bioengineered. 2021;12:5428\u201339. https:\/\/doi.org\/10.1080\/21655979.2021.1967029.","journal-title":"Bioengineered"},{"key":"7206_CR43","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/path.4801","volume":"240","author":"N Ieronimakis","year":"2016","unstructured":"Ieronimakis N, Hays A, Prasad A, Janebodin K, Duffield JS, Reyes M. PDGFR\u03b1 signalling promotes fibrogenic responses in collagen-producing cells in Duchenne muscular dystrophy. J Pathol. 2016;240:410\u201324. https:\/\/doi.org\/10.1002\/path.4801.","journal-title":"J Pathol"},{"key":"7206_CR44","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.bbadis.2018.10.029","volume":"1865","author":"A-M Siegert","year":"2019","unstructured":"Siegert A-M, Garc\u00eda D\u00edaz-Barriga G, Esteve-Codina A, Navas-Madro\u00f1al M, Del Gorbenko D, Alberch J, Heath S, Gal\u00e1n M, Egea G. A FBN1 3\u2019UTR mutation variant is associated with endoplasmic reticulum stress in aortic aneurysm in Marfan syndrome. Biochim Biophys Acta Mol Basis Dis. 2019;1865:107\u201314. https:\/\/doi.org\/10.1016\/j.bbadis.2018.10.029.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"7206_CR45","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/rheumatology\/kel450","volume":"46","author":"G Percheron","year":"2007","unstructured":"Percheron G, Fayet G, Ningler T, Le Parc JM, Denot-Ledunois S, Leroy M, Raffestin B, Jondeau G. Muscle strength and body composition in adult women with Marfan syndrome. Rheumatology (Oxford). 2007;46:957\u201362.","journal-title":"Rheumatology (Oxford)"},{"key":"7206_CR46","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nm1536","volume":"13","author":"RD Cohn","year":"2007","unstructured":"Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, Gamradt M, ap Rhys CM, Holm TM, Loeys BL, et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med. 2007;13:204\u201310.","journal-title":"Nat Med"},{"key":"7206_CR47","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1136\/jnnp.74.5.633","volume":"74","author":"WMH Behan","year":"2003","unstructured":"Behan WMH, Longman C, Petty RKH, Comeglio P, Child AH, Boxer M, Foskett P, Harriman DGF. Muscle fibrillin deficiency in Marfan\u2019s syndrome myopathy. J Neurol Neurosurg Psychiatry. 2003;74:633\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7206_CR48","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng1116","volume":"33","author":"ER Neptune","year":"2003","unstructured":"Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, Ramirez F, Sakai LY, Dietz HC. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003;33:407\u201311.","journal-title":"Nat Genet"},{"key":"7206_CR49","doi-asserted-by":"publisher","first-page":"82ra37","DOI":"10.1126\/scitranslmed.3002227","volume":"3","author":"TN Burks","year":"2011","unstructured":"Burks TN, Andres-Mateos E, Marx R, Mejias R, Van Erp C, Simmers JL, Walston JD, Ward CW, Cohn RD. Losartan restores skeletal muscle remodeling and protects against disuse atrophy in Sarcopenia. Sci Transl Med. 2011;3:82ra37. https:\/\/doi.org\/10.1126\/scitranslmed.3002227.","journal-title":"Sci Transl Med"},{"key":"7206_CR50","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/prca.201300072","volume":"8","author":"F Cynthia Martin","year":"2014","unstructured":"Cynthia Martin F, Hiller M, Spitali P, Oonk S, Dalebout H, Palmblad M, Chaouch A, Guglieri M, Straub V, Lochm\u00fcller H, et al. Fibronectin is a serum biomarker for Duchenne muscular dystrophy. Proteom Clin Appl. 2014;8:269\u201378. https:\/\/doi.org\/10.1002\/prca.201300072.","journal-title":"Proteom Clin Appl"},{"key":"7206_CR51","doi-asserted-by":"publisher","first-page":"4626","DOI":"10.1093\/bioinformatics\/btaa563","volume":"36","author":"Y Peng","year":"2020","unstructured":"Peng Y, Yuan M, Xin J, Liu X, Wang J. Screening novel drug candidates for Alzheimer\u2019s disease by an integrated network and transcriptome analysis. Bioinformatics. 2020;36:4626\u201332. https:\/\/doi.org\/10.1093\/bioinformatics\/btaa563.","journal-title":"Bioinformatics"},{"key":"7206_CR52","doi-asserted-by":"publisher","unstructured":"Morgan J, Partridge T. Skeletal muscle in health and disease. Dis Model Mech. 2020;13. https:\/\/doi.org\/10.1242\/dmm.042192.","DOI":"10.1242\/dmm.042192"},{"key":"7206_CR53","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1002\/cncr.24879","volume":"116","author":"YD Saito","year":"2010","unstructured":"Saito YD, Jensen AR, Salgia R, Posadas EM. Fyn: a novel molecular target in cancer. Cancer. 2010;116:1629\u201337. https:\/\/doi.org\/10.1002\/cncr.24879.","journal-title":"Cancer"},{"key":"7206_CR54","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1146\/annurev.pharmtox.41.1.751","volume":"41","author":"SF Steinberg","year":"2001","unstructured":"Steinberg SF, Brunton LL. Compartmentation of G protein-coupled signaling pathways in cardiac myocytes. Annu Rev Pharmacol Toxicol. 2001;41:751\u201373.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"7206_CR55","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1083\/jcb.200601160","volume":"173","author":"R Rudolf","year":"2006","unstructured":"Rudolf R, Magalh\u00e3es PJ, Pozzan T. Direct in vivo monitoring of sarcoplasmic reticulum Ca2\u2009+\u2009and cytosolic cAMP dynamics in mouse skeletal muscle. J Cell Biol. 2006;173:187\u201393.","journal-title":"J Cell Biol"},{"key":"7206_CR56","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1021\/acs.jafc.5b04956","volume":"64","author":"L Zhao","year":"2016","unstructured":"Zhao L, Yang S, Zhang Y, Zhang Y, Hou C, Cheng Y, You X, Gu X, Zhao Z, Muhammad Tarique T. New Analytical Tool for the detection of ractopamine abuse in Goat skeletal muscle by potential gene expression biomarkers. J Agric Food Chem. 2016;64:1861\u20137. https:\/\/doi.org\/10.1021\/acs.jafc.5b04956.","journal-title":"J Agric Food Chem"},{"key":"7206_CR57","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s10067-020-05311-0","volume":"40","author":"C Zhao","year":"2021","unstructured":"Zhao C. Identifying the hub gene and immune infiltration of osteoarthritis by bioinformatical methods. Clin Rheumatol. 2021;40:1027\u201337. https:\/\/doi.org\/10.1007\/s10067-020-05311-0.","journal-title":"Clin Rheumatol"},{"key":"7206_CR58","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/nbt936","volume":"22","author":"A Reynolds","year":"2004","unstructured":"Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol. 2004;22:326\u201330. https:\/\/doi.org\/10.1038\/nbt936.","journal-title":"Nat Biotechnol"},{"key":"7206_CR59","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Q Cheng","year":"2020","unstructured":"Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020;15:313\u201320. https:\/\/doi.org\/10.1038\/s41565-020-0669-6.","journal-title":"Nat Nanotechnol"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-024-07206-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-024-07206-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-024-07206-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T05:02:58Z","timestamp":1716008578000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-024-07206-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,18]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["7206"],"URL":"https:\/\/doi.org\/10.1186\/s12891-024-07206-6","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,18]]},"assertion":[{"value":"18 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Approval of this study was granted by Ethics Committee of Sports Science Experiments of Beijing Sport University (2020049\u00a0A) and in accordance with ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"386"}}